India, May 8 -- CAMP4 Therapeutics Corporation (CAMP), a clinical-stage biopharmaceutical company, on Thursday released its first-quarter financial results and provided various business highlights.
The company specializes in developing RNA-targeted therapies to upregulate gene expression to effectively treat genetic diseases.
Q1 2026:
The company reported a net loss of $18.33 million, or $0.32 per share, in Q1 2026, while in the same period of 2025, the net loss was $12.43 million, or $0.62 per share.
Research and development expenses (R&D) were $10.16 million, relatively stable compared to $10.15 million in the previous year.
Cash, cash equivalents, and marketable securities on March 31, 2026, amounted to $99.21 million.
googletag.cm...